Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016364201> ?p ?o ?g. }
- W3016364201 endingPage "709" @default.
- W3016364201 startingPage "699" @default.
- W3016364201 abstract "Background State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined with carboplatin–paclitaxel or carboplatin–gemcitabine) or the most active non-bevacizumab regimen: carboplatin–pegylated liposomal doxorubicin. The aim of this head-to-head trial was to compare a standard bevacizumab-containing regimen versus carboplatin–pegylated liposomal doxorubicin combined with bevacizumab. Methods This multicentre, open-label, randomised, phase 3 trial, was done in 159 academic centres in Germany, France, Australia, Austria, and the UK. Eligible patients (aged ≥18 years) had histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with first disease recurrence more than 6 months after first-line platinum-based chemotherapy, and an Eastern Cooperative Oncology Group performance status of 0–2. Patients were stratified by platinum-free interval, residual tumour, previous antiangiogenic therapy, and study group language, and were centrally randomly assigned 1:1 using randomly permuted blocks of size two, four, or six to receive six intravenous cycles of bevacizumab (15 mg/kg, day 1) plus carboplatin (area under the concentration curve [AUC] 4, day 1) plus gemcitabine (1000 mg/m2, days 1 and 8) every 3 weeks or six cycles of bevacizumab (10 mg/kg, days 1 and 15) plus carboplatin (AUC 5, day 1) plus pegylated liposomal doxorubicin (30 mg/m2, day 1) every 4 weeks, both followed by maintenance bevacizumab (15 mg/kg every 3 weeks in both groups) until disease progression or unacceptable toxicity. There was no masking in this open-label trial. The primary endpoint was investigator-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumors version 1.1. Efficacy data were analysed in the intention-to-treat population. Safety was analysed in all patients who received at least one dose of study drug. This completed study is registered with ClinicalTrials.gov, NCT01837251. Findings Between Aug 1, 2013, and July 31, 2015, 682 eligible patients were enrolled, of whom 345 were randomly assigned to receive carboplatin–pegylated liposomal doxorubicin–bevacizumab (experimental group) and 337 were randomly assigned to receive carboplatin–gemcitabine–bevacizumab (standard group). Median follow-up for progression-free survival at data cutoff (July 10, 2018) was 12·4 months (IQR 8·3–21·7) in the experimental group and 11·3 months (8·0–18·4) in the standard group. Median progression-free survival was 13·3 months (95% CI 11·7–14·2) in the experimental group versus 11·6 months (11·0–12·7) in the standard group (hazard ratio 0·81, 95% CI 0·68–0·96; p=0·012). The most common grade 3 or 4 adverse events were hypertension (88 [27%] of 332 patients in the experimental group vs 67 [20%] of 329 patients in the standard group) and neutropenia (40 [12%] vs 73 [22%]). Serious adverse events occurred in 33 (10%) of 332 patients in the experimental group and 28 (9%) of 329 in the standard group. Treatment-related deaths occurred in one patient in the experimental group (<1%; large intestine perforation) and two patients in the standard group (1%; one case each of osmotic demyelination syndrome and intracranial haemorrhage). Interpretation Carboplatin–pegylated liposomal doxorubicin–bevacizumab is a new standard treatment option for platinum-eligible recurrent ovarian cancer. Funding F Hoffmann-La Roche." @default.
- W3016364201 created "2020-04-24" @default.
- W3016364201 creator A5002333415 @default.
- W3016364201 creator A5002536098 @default.
- W3016364201 creator A5002555374 @default.
- W3016364201 creator A5002739406 @default.
- W3016364201 creator A5003246186 @default.
- W3016364201 creator A5003678097 @default.
- W3016364201 creator A5004160287 @default.
- W3016364201 creator A5006360930 @default.
- W3016364201 creator A5006415190 @default.
- W3016364201 creator A5007674739 @default.
- W3016364201 creator A5008264203 @default.
- W3016364201 creator A5008586146 @default.
- W3016364201 creator A5008832472 @default.
- W3016364201 creator A5009000244 @default.
- W3016364201 creator A5010185711 @default.
- W3016364201 creator A5010710488 @default.
- W3016364201 creator A5010940695 @default.
- W3016364201 creator A5011232197 @default.
- W3016364201 creator A5011534450 @default.
- W3016364201 creator A5012023155 @default.
- W3016364201 creator A5012733931 @default.
- W3016364201 creator A5012827037 @default.
- W3016364201 creator A5013142812 @default.
- W3016364201 creator A5013148496 @default.
- W3016364201 creator A5014193307 @default.
- W3016364201 creator A5014722961 @default.
- W3016364201 creator A5014938046 @default.
- W3016364201 creator A5015610680 @default.
- W3016364201 creator A5016766526 @default.
- W3016364201 creator A5016852436 @default.
- W3016364201 creator A5016987068 @default.
- W3016364201 creator A5018378577 @default.
- W3016364201 creator A5018801649 @default.
- W3016364201 creator A5019412820 @default.
- W3016364201 creator A5020142852 @default.
- W3016364201 creator A5021367756 @default.
- W3016364201 creator A5021427123 @default.
- W3016364201 creator A5021807771 @default.
- W3016364201 creator A5022300936 @default.
- W3016364201 creator A5022527560 @default.
- W3016364201 creator A5023727769 @default.
- W3016364201 creator A5025215479 @default.
- W3016364201 creator A5026269617 @default.
- W3016364201 creator A5026393946 @default.
- W3016364201 creator A5026648066 @default.
- W3016364201 creator A5028513237 @default.
- W3016364201 creator A5028895212 @default.
- W3016364201 creator A5029135854 @default.
- W3016364201 creator A5029807906 @default.
- W3016364201 creator A5030954166 @default.
- W3016364201 creator A5033818053 @default.
- W3016364201 creator A5034695241 @default.
- W3016364201 creator A5034922000 @default.
- W3016364201 creator A5035050460 @default.
- W3016364201 creator A5035772972 @default.
- W3016364201 creator A5037650974 @default.
- W3016364201 creator A5038386249 @default.
- W3016364201 creator A5039809366 @default.
- W3016364201 creator A5040171322 @default.
- W3016364201 creator A5040195796 @default.
- W3016364201 creator A5041927534 @default.
- W3016364201 creator A5042766157 @default.
- W3016364201 creator A5043184973 @default.
- W3016364201 creator A5043603003 @default.
- W3016364201 creator A5043759675 @default.
- W3016364201 creator A5044020087 @default.
- W3016364201 creator A5044300677 @default.
- W3016364201 creator A5044372455 @default.
- W3016364201 creator A5045041265 @default.
- W3016364201 creator A5045044895 @default.
- W3016364201 creator A5045766264 @default.
- W3016364201 creator A5047370734 @default.
- W3016364201 creator A5047695952 @default.
- W3016364201 creator A5047757604 @default.
- W3016364201 creator A5048438467 @default.
- W3016364201 creator A5048515502 @default.
- W3016364201 creator A5050336778 @default.
- W3016364201 creator A5051245507 @default.
- W3016364201 creator A5051429857 @default.
- W3016364201 creator A5052499727 @default.
- W3016364201 creator A5052512508 @default.
- W3016364201 creator A5052709676 @default.
- W3016364201 creator A5052920067 @default.
- W3016364201 creator A5052979812 @default.
- W3016364201 creator A5053388612 @default.
- W3016364201 creator A5055020479 @default.
- W3016364201 creator A5055136263 @default.
- W3016364201 creator A5055272754 @default.
- W3016364201 creator A5055838207 @default.
- W3016364201 creator A5056412323 @default.
- W3016364201 creator A5056456837 @default.
- W3016364201 creator A5056466058 @default.
- W3016364201 creator A5056688392 @default.
- W3016364201 creator A5056795901 @default.
- W3016364201 creator A5056961294 @default.
- W3016364201 creator A5057168528 @default.